BU and GSK Announce Collaboration to Pioneer New Lung Disease Treatments
An exciting new collaboration between the pharmaceutical company GSK and pulmonary researchers in the CReM has been newly been established. This partnership will further advances against pulmonary fibrosis, with the hope of finding new treatments and cures. As a collaborating partner, GSK will provide support in the form of funding and access to patient specimens. In the words of Professor Darrell Kotton, “This exciting collaboration with GSK will help BU, BMC, and CReM to make meaningful progress in the treatment of chronic lung diseases like pulmonary fibrosis… Together with GSK, we are poised to advance emerging research discoveries into real-world therapies for patients.”